Importance:
Late recurrence (more than 2 years) after liver resection for hepatocellular carcinoma (HCC) is generally considered as a multicentric tumor or a de novo cancer.
Objective:
To investigate the risk factors, patterns, and outcomes of late recurrence after curative liver resection for HCC.
Design, Setting, And Participants:
This study was a multicenter retrospective analysis of patients who underwent curative liver resection for HCC at 6 hospitals in China from January 2001 to December 2015. Among 734 patients who were alive and free of recurrence at 2 years after resection, 303 patients developed late recurrence. Data were analyzed from June 2017 to February 2018.
Interventions:
Liver resection for HCC.
Main Outcomes And Measures:
Risk factors of late recurrence as well as patterns, treatments, and long-term outcomes of patients with late recurrence. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors of late recurrence.
Results:
Of the included 734 patients, 652 (88.8%) were male, and the mean (SD) age was 51.0 (10.3) years. At a median (interquartile range) follow-up of 78.0 (52.8-112.5) months, 303 patients (41.3%) developed late recurrence. Multivariate analysis revealed that male sex, cirrhosis, multiple tumors, satellite nodules, tumor size greater than 5 cm, and macroscopic and microscopic vascular invasion were independent risk factors of late recurrence. Of the 303 patients with late recurrence, 273 (90.1%) had only intrahepatic recurrence, 30 (9.9%) had both intrahepatic and extrahepatic recurrence, and none had only extrahepatic recurrence. Potentially curative treatments were given to 165 of 303 patients (54.5%) with late recurrence, which included reresection, transplant, and local ablation. Multivariate Cox regression analysis showed that regular surveillance for postoperative recurrence (hazard ratio [HR], 0.470; 95% CI, 0.310-0.713; P = .001), cirrhosis (HR, 1.381; 95% CI, 1.049-1.854; P = .02), portal hypertension (HR, 2.424; 95% CI, 1.644-3.574; P < .001), Child-Pugh grade of B or C (HR, 1.376; 95% CI, 1.153-1.674; P < .001), Barcelona Clinic Liver Cancer stage B (HR, 1.304; 95% CI, 1.007-1.708; P = .04) and stage C (HR, 2.037; 95% CI, 1.583-2.842; P < .001), and potentially curative treatment (HR, 0.443; 95% CI, 0.297-0.661; P < .001) were independent predictors of overall survival for patients with late recurrence.
Conclusions And Relevance:
Late recurrence after HCC resection was associated with sex, cirrhosis, and several aggressive tumor characteristics of the initial HCC. The patterns of late recurrence suggested surveillance for recurrence after 2 years of surgery should be targeted to the liver. Postoperative surveillance improved the chance of potentially curative treatments, with improved survival outcomes in patients with late recurrence.
Citing Articles
Spatial immune scoring system predicts hepatocellular carcinoma recurrence.
Jia G, He P, Dai T, Goh D, Wang J, Sun M
Nature. 2025; .
PMID: 40074893
DOI: 10.1038/s41586-025-08668-x.
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China.
Zhang X, Zhang T, Wu F, Li Z, Xiao Z, Yu Z
Hepatol Int. 2025; .
PMID: 40063322
DOI: 10.1007/s12072-025-10802-w.
Enhanced prediction of 5-year postoperative recurrence in hepatocellular carcinoma by incorporating LASSO regression and random forest models.
Su B, Zhu C, Cao J, Peng R, Tu D, Jiang G
Surg Endosc. 2025; .
PMID: 40032663
DOI: 10.1007/s00464-025-11631-6.
Radiofrequency ablation for peribiliary hepatocellular carcinoma: propensity score matching analysis.
Cui J, Sui X, Liu K, Huang M, Zheng Y, Zhao X
Insights Imaging. 2025; 16(1):45.
PMID: 39971810
PMC: 11839967.
DOI: 10.1186/s13244-025-01919-5.
Radiofrequency ablation of hepatocellular carcinoma: Current status, challenges, and prospects.
Wang H, Wu Z, Cui D, Shi Y, Zhai B
Liver Res. 2025; 7(2):108-115.
PMID: 39958948
PMC: 11791925.
DOI: 10.1016/j.livres.2023.05.002.
Hepatocellular carcinoma recurrence: Predictors and management.
Abdelhamed W, El-Kassas M
Liver Res. 2025; 7(4):321-332.
PMID: 39958776
PMC: 11791921.
DOI: 10.1016/j.livres.2023.11.004.
Novel online calculator to predict reduced risk of early recurrence from adjuvant transarterial chemoembolisation for patients with hepatocellular carcinoma.
Chen W, Li C, Liu Z, Kong Q, Sun L, Zeng Y
eGastroenterology. 2025; 1(1):e100008.
PMID: 39944245
PMC: 11770458.
DOI: 10.1136/egastro-2023-100008.
Identification of the entosis-related prognostic signature and tumour microenvironment in hepatocellular carcinoma on the basis of bioinformatics analysis and experimental validation.
Wu C, Fang S, Wu L, Mi Z, Yin Y, Liao Y
Clin Exp Med. 2025; 25(1):55.
PMID: 39937284
PMC: 11821697.
DOI: 10.1007/s10238-025-01580-8.
Association of preoperative frailty with short- and long-term outcomes after hepatic resection for elderly patients with hepatocellular carcinoma: multicentre analysis.
Diao Y, Li D, Wu H, Yang Y, Wang N, Gu W
BJS Open. 2025; 9(1).
PMID: 39921532
PMC: 11806262.
DOI: 10.1093/bjsopen/zrae171.
The role of lnc‑MAPKAPK5‑AS1 in immune cell infiltration in hepatocellular carcinoma: Bioinformatics analysis and validation.
Hu X, Wang D, Chen J, Liang B, Zhang L, Qin P
Oncol Lett. 2025; 29(3):141.
PMID: 39850723
PMC: 11755229.
DOI: 10.3892/ol.2025.14887.
Impact of postoperative morbidity on the prognosis of patients with hepatocellular carcinoma after laparoscopic liver resection: a multicenter observational study.
Yang S, Ni H, Zhang A, Zhang J, Zang H, Ming Z
Sci Rep. 2025; 15(1):1724.
PMID: 39799160
PMC: 11724855.
DOI: 10.1038/s41598-024-85020-9.
Liver resection and transplantation in the era of checkpoint inhibitors.
Tabrizian P, Marino R, Chow P
JHEP Rep. 2025; 6(11):101181.
PMID: 39741696
PMC: 11686060.
DOI: 10.1016/j.jhepr.2024.101181.
Laparoscopic hepatectomy versus microwave ablation for multifocal 3-5 cm hepatocellular carcinoma: a multi-centre, real-world study.
Wang Z, Pang C, Meng Q, Zhang D, Hong Z, He G
Int J Surg. 2024; 110(11):6911-6921.
PMID: 39699863
PMC: 11573104.
DOI: 10.1097/JS9.0000000000001398.
Update on Resection Strategies for Hepatocellular Carcinoma: A Narrative Review.
Lee J, Choi H, Kim J, Lee T, Yoon Y
Cancers (Basel). 2024; 16(23).
PMID: 39682279
PMC: 11640626.
DOI: 10.3390/cancers16234093.
Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis.
Jiang F, Dang Y, Zhang Z, Yan Y, Wang Y, Chen Y
mSystems. 2024; 10(1):e0076524.
PMID: 39660866
PMC: 11748501.
DOI: 10.1128/msystems.00765-24.
Deciphering the Prognostic and Therapeutic Value of a Gene Model Associated with Two Aggressive Hepatocellular Carcinoma Phenotypes Using Machine Learning.
Pan J, Zhang C, Huang H, Zhu Y, Zhang Y, Wu S
J Hepatocell Carcinoma. 2024; 11:2373-2390.
PMID: 39634327
PMC: 11614714.
DOI: 10.2147/JHC.S480358.
Non-radiomics imaging (US-CEUS) features and clinical text features: correlation with microvascular invasion and tumor grading in hepatocellular carcinoma.
Yang Q, Zhou J, Luo B, Zheng R, Liao J, Tang L
Abdom Radiol (NY). 2024; .
PMID: 39607454
DOI: 10.1007/s00261-024-04659-0.
Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review.
Li J, Liu Y, Qiu Y, Qu C, Li J
Front Immunol. 2024; 15:1487353.
PMID: 39588371
PMC: 11586331.
DOI: 10.3389/fimmu.2024.1487353.
Construction of a 2.5D Deep Learning Model for Predicting Early Postoperative Recurrence of Hepatocellular Carcinoma Using Multi-View and Multi-Phase CT Images.
Zhang Y, Chen Z, Bu Y, Lei P, Yang W, Zhang W
J Hepatocell Carcinoma. 2024; 11:2223-2239.
PMID: 39569409
PMC: 11577935.
DOI: 10.2147/JHC.S493478.
The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.
Huang J, Zhou Y, Wei S, Tang Y, Zhang Q, Tang Y
Front Oncol. 2024; 14:1359017.
PMID: 39555448
PMC: 11563962.
DOI: 10.3389/fonc.2024.1359017.